EFSA J 14, e04629
Crit Rev Biotechnol 10:205222 Kera Y, Kiriyama T, Komura S (1985) Conjugation of acetaldehyde with cysteinylglycine, the first metabolite in glutathione breakdown by gamma-glutamyltranspeptidase
In one embodiment, when one or more buffers are utilized in the formulations or compositions of the present disclosure, they are combined, e.g., with a pharmaceutically acceptable vehicle and are present in the final formulation or composition, e.g., in an amount ranging from about 0.1% to about 20%, from about 0.5% to about 10%
Theyre marketed for recovery and skin/tissue repair, but theyre sold strictly for research use only, with no human trials on the blends themselves and no quality oversight (Protide Health)
Human clinical data remains limited for both forms